Saturday, July 30, 2016
Ligand announces multi-program LTP technology licensing agreement with nucorion pharmaceuticals. Newly-Formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets.
Eligible to receive milestone payments as well as royalties ranging from 5% to 9% on net sales of products developed by Nucorion under agreement.
Ligand announces multi-program LTP technology licensing agreement with Nucorion pharmaceuticals.
Source : reuters.com
